Entacapone in elderly parkinsonian patients experiencing levodopa-related wearing-off: A pilot study

Clelia Pellicano, Dario Benincasa, Morena Giovannelli, Francesca R. Buttarelli, Stefano Ruggieri, Francesco E. Pontieri

Research output: Contribution to journalArticlepeer-review


Levodopa (LD) provides the most effective symptomatic treatment for Parkinson's disease (PD). Long-term treatment with LD, however, is often associated with the development of response fluctuations. Previous evidence suggests that the short half-life of LD is a major contributor to the development of response fluctuations and the wearing-off phenomenon in particular. Entacapone, a peripheral catechol-O-methyltransferase inhibitor has been shown to reduce OFF time and increase ON time in several therapeutic trials on PD patients treated with LD experiencing motor fluctuations. However, data are missing on the tolerability and efficacy of entacapone in elderly PD patients. This is of particular relevance, as most PD patients develop LD-related motor fluctuations after several years of disease duration. Here we report that addition of entacapone in a group of 45 elderly PD patients with LD-related motor fluctuations is well tolerated and efficacious in reducing the time, frequency and severity of the OFF periods. These data suggest that the drug can be used safely and efficaciously in elderly PD patients.

Original languageEnglish
Pages (from-to)74-76
Number of pages3
JournalNeurological Research
Issue number1
Publication statusPublished - Feb 2009


  • Elderly
  • Entacapone
  • Parkinson's disease
  • Wearing-off

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Entacapone in elderly parkinsonian patients experiencing levodopa-related wearing-off: A pilot study'. Together they form a unique fingerprint.

Cite this